Clinical researchers at AACR discussed a wide range of approaches focusing on several different potential use-cases in the detection or assessment of early cancers.
The company presented new data on the performance of a multi-pronged liquid biopsy assay in detecting colorectal cancers across a range of clinical stages.
Data being presented at the upcoming AACR meeting show that Guardant's liquid biopsy test provided more accurate and rapid mutation detection than tissue genotyping.
The company is eyeing a launch for its IVD kits at the beginning of next year, as evidence grows for the integration of TMB analysis into the clinical care of cancer patients.
The firm presented on its pancreatic, breast, and prostate cancer programs, the latter of which is moving through clinical validation toward commercialization.
Presentations largely reflected negatively on the utility of PD-L1 for stratifying response, but pivotal new data on tumor mutational burden as assessed by Foundation Medicine's genomic sequencing panel.
